ERBB2 and breast carcinoma: The addition of TRZ to adjuvant chemotherapy in patients with HER2 positive breast cancer was unequivocally beneficial, facilitating a 50% decrease in the risk of cancer relapse and a 33% decrease in mortality [7-12].